Last reviewed · How we verify
BPaQM — Competitive Intelligence Brief
phase 3
Antimalarial
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
BPaQM (BPaQM) — Otsuka Pharmaceutical Development & Commercialization, Inc.. BPaQM is a novel antimalarial compound that acts as a blood schizonticide to prevent malaria parasite multiplication in red blood cells.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BPaQM TARGET | BPaQM | Otsuka Pharmaceutical Development & Commercialization, Inc. | phase 3 | Antimalarial | ||
| Coartem | LUMEFANTRINE | Novartis | marketed | Antimalarial [EPC] | Potassium voltage-gated channel subfamily H member 2 | 2009-01-01 |
| Coartem | ARTEMETHER | marketed | Antimalarial [EPC] | 2009-01-01 | ||
| Qualaquin | QUININE | Sun Pharm Industries | marketed | Antimalarial | Sodium channel alpha subunits; brain (Types I, II, III) | 2005-01-01 |
| Malarone | PROGUANIL | GSK | marketed | Antimalarial [EPC] | 2000-01-01 | |
| Mepron | ATOVAQUONE | marketed | Antimalarial [EPC] | ATP-binding cassette sub-family G member 2 | 1992-01-01 | |
| Halfan | HALOFANTRINE | GSK | marketed | Antimalarial | Potassium voltage-gated channel subfamily H member 2 | 1992-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antimalarial class)
- London School of Hygiene and Tropical Medicine · 6 drugs in this class
- Sanofi · 3 drugs in this class
- Epicentre · 2 drugs in this class
- University of Oxford · 2 drugs in this class
- · 2 drugs in this class
- Frantz Viral Therapeutics, LLC · 1 drug in this class
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
- Institut de Recherche pour le Developpement · 1 drug in this class
- Centre de Recherche Médicale de Lambaréné · 1 drug in this class
- GlaxoSmithKline · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BPaQM CI watch — RSS
- BPaQM CI watch — Atom
- BPaQM CI watch — JSON
- BPaQM alone — RSS
- Whole Antimalarial class — RSS
Cite this brief
Drug Landscape (2026). BPaQM — Competitive Intelligence Brief. https://druglandscape.com/ci/bpaqm. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab